Literature DB >> 2704030

Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency.

T R Jones1, T J Thornton, A Flinn, A L Jackman, D R Newell, A H Calvert.   

Abstract

The poor solubility of the thymidylate synthase (TS) inhibiting antifolate 10-propargyl-5,8-dideazafolic acid has posed problems for its clinical use and is probably responsible for its renal toxicity. The insolubility is caused by the 2-amino-3,4-dihydro-4-oxopyrimidine moiety of the drug which stabilizes the solid state by intermolecular hydrogen bonding. In examining this moiety we have removed the 2-amino group and now report on 2-desamino-10-propargyl-5,8-dideazafolic acid (8e) and four analogues with H, Me, Et, and allyl at N10. 3,4-Dihydro-4-oxo-6-methylquinazoline was solubilized by alkylating the lactam nitrogen with chloromethyl pivalate. Reaction with N-bromosuccinimide gave the corresponding 6-bromomethyl compound, which was coupled with diethyl N-(4-aminobenzoyl)-L-glutamate or the appropriate N-substituted derivative thereof. The quinazoline N3 nitrogen and carboxyl groups in the product were simultaneously deprotected by cold alkali in the final step to give the desired five antifolates. These were tested against L1210 TS and it was found that removal of the 2-amino group caused a slight (3-9-fold) loss of TS inhibition. 8e was only 8-fold a lesser TS inhibitor than the parent drug. Inhibition of rat liver dihydrofolate reductase was reduced by over 1 order of magnitude for three compounds tested. All five analogues were more cytotoxic to L1210 cells in culture than their 2-amino counterparts; 8e was 8.5-fold more active with an ID50 of 0.4 microM. This remarkable result probably owes to increased cellular penetration. 8e was 5-fold more soluble than 1 at pH 5.0 and greater than 340-fold more soluble at pH 7.4.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2704030     DOI: 10.1021/jm00124a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Clinical and preclinical pharmacokinetics of raltitrexed.

Authors:  S J Clarke; P J Beale; L P Rivory
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 2.  Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Authors:  A L Jackman; F T Boyle; K R Harrap
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.

Authors:  C Erlichman; B Mitrovski
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats.

Authors:  D I Jodrell; D R Newell; W Gibson; L R Hughes; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.

Authors:  B Mitrovski; J Pressacco; S Mandelbaum; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.

Authors:  M I Walton; F Mitchell; G W Aherne; C J Medlow; F T Boyle; A L Jackman
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

7.  Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.

Authors:  A L Jackman; L R Kelland; R Kimbell; M Brown; W Gibson; G W Aherne; A Hardcastle; F T Boyle
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.